Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.51 |
| ▸ | FNTB | P49356 | 14/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 13/20 | 0.51 |
| ▸ | NPY4R | P50391 | 3/20 | 0.44 |
| ▸ | NPY1R | P25929 | 2/20 | 0.44 |
| ▸ | NPY2R | P49146 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30761725 | 0.98 | FNTA (0.49) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL30479333 | 0.96 | FNTA (0.51) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL15011155 | 0.95 | FNTA (0.54) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL2543473 | 0.95 | FNTA (0.54) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL9189133 | 0.95 | FNTA (0.54) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL29619999 | 0.94 | FNTA (0.47) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL30599476 | 0.93 | FNTA (0.46) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL30216531 | 0.92 | FNTA (0.47) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL30905090 | 0.92 | NPY4R (0.46) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL29498257 | 0.92 | NPY4R (0.46) | FNTAFNTBPGGT1BNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12613247-B2 | Labelling method to distinguish isobaric amino acids and amino acid combinations | RAPID NOVOR INC. (CA) | 2026-04-28 | — | — | US | claimed |
| EP-3831358-B1 | PEPTIDES AND COMPOSITIONS FOR USE IN COSMETICS AND MEDICINE | LIPOTRUE S L (ES) | 2025-03-12 | — | — | EP | claimed |
| EP-3899532-B1 | A LABELLING METHOD TO DISTINGUISH ISOBARIC AMINO ACIDS AND AMINO ACID COMBINATIONS | RAPID NOVOR INC (CA) | 2024-02-14 | — | — | EP | claimed |
| US-20220389058-A1 | PEPTIDES AND COMPOSITIONS FOR USE IN COSMETICS AND MEDICINE | LIPOTRUE, S.L. (ES) | 2022-12-08 | — | — | US | claimed |
| CN-115175654-A | Peptides and compositions for use in cosmetics and pharmaceuticals | 利波特鲁有限公司 | 2022-10-11 | — | — | CN | claimed |
| US-12613247-B2 | Labelling method to distinguish isobaric amino acids and amino acid combinations | RAPID NOVOR INC. (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-4321524-B1 | LIPID AND COMPOSITION | SOGO PHARM (JP) | 2025-12-10 | — | — | EP | disclosed |
| CN-115873803-B | Method for improving NK cell survival and anti-tumor activity and application thereof | 上海恩凯细胞技术有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-3831358-B1 | PEPTIDES AND COMPOSITIONS FOR USE IN COSMETICS AND MEDICINE | LIPOTRUE S L (ES) | 2025-03-12 | — | — | EP | disclosed |
| CN-118308367-B | Mulberry MaWRKY gene and application thereof | 成都师范学院 | 2024-11-29 | — | — | CN | disclosed |
| CN-118813570-A | Flavone glycosyltransferase, mutant and application thereof | 井冈山大学 | 2024-10-22 | — | — | CN | disclosed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | disclosed |
| CN-114933634-A | Synthesis method of acetyl hexapeptide | 陕西未来多肽生物科技有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-113373194-B | Perilla seed peptide capable of improving male sexual function and preparation method thereof | 中国食品发酵工业研究院有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20220202714-A1 | CELL PENETRATING PEPTIDE (CPP)-MEDIATED EV LOADING | EVOX THERAPEUTICS LTD (GB) | 2022-06-30 | — | — | US | disclosed |
| US-11369598-B2 | Treatment of T-cell mediated diseases | AMPIO PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3991791-A1 | AMINO ACID MIXTURE HAVING CO-AMORPHOUS STRUCTURE | AJINOMOTO CO., INC. (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-11312974-B2 | Gene for increasing plant biomass and use therefor | KANEKA CORPORATION (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20220112237-A1 | AMINO ACID COMPOSITION HAVING CO-AMORPHOUS STRUCTURE | AJINOMOTO CO., INC. (JP) | 2022-04-14 | — | — | US | disclosed |
| US-11298319-B2 | Cell penetrating peptide (CPP)-mediated EV loading | EVOX THERAPEUTICS LTD (GB) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12613247-B2 | Labelling method to distinguish isobaric amino acids and amino acid combinations | DNPEP, ASNS, ANPEP | FNTA 1623/4885FNTB 862/4885PGGT1B 414/4885 |
| US-11369598-B2 | Treatment of T-cell mediated diseases | IL15, CD4, IL5 | FNTA 1204/4885FNTB 2841/4885PGGT1B 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.